Diseases of immune dysregulation: Difference between revisions
Jump to navigation
Jump to search
| Line 78: | Line 78: | ||
| pmid = 8717042 | | pmid = 8717042 | ||
}}</ref> | }}</ref> | ||
* It is characterized by [[photophobia]], [[nystagmus]], [[Albinism|partial albinism]], [[neutropenia]], abnormal susceptibility to [[Infection|infections]] and [[Lymphoma (patient information)|malignant lymphoma]], large [[Eosinophil granulocyte|eosinophilic]] [[peroxidase]] positive inclusion bosides in [[Myeloblast|myeloblasts]] and [[Promyelocyte|promyelocytes]] of [[bone marrow]]. | * It is characterized by [[photophobia]], [[nystagmus]], [[Albinism|partial albinism]], [[neutropenia]], abnormal susceptibility to [[Infection|infections]] and [[Lymphoma (patient information)|malignant lymphoma]], large [[Eosinophil granulocyte|eosinophilic]] [[peroxidase]] positive inclusion bosides in [[Myeloblast|myeloblasts]] and [[Promyelocyte|promyelocytes]] of [[bone marrow]].<ref name="KaplanDe Domenico2008">{{cite journal|last1=Kaplan|first1=Jerry|last2=De Domenico|first2=Ivana|last3=Ward|first3=Diane McVey|title=Chediak-Higashi syndrome|journal=Current Opinion in Hematology|volume=15|issue=1|year=2008|pages=22–29|issn=1065-6251|doi=10.1097/MOH.0b013e3282f2bcce}}</ref> | ||
* The most effective treatment is [[Stem cell transplantation|hematopoeitic stem cell transplantation]].<ref>{{Cite journal | * The most effective treatment is [[Stem cell transplantation|hematopoeitic stem cell transplantation]].<ref>{{Cite journal | ||
| author = [[M. Eapen]], [[C. A. DeLaat]], [[K. S. Baker]], [[M. S. Cairo]], [[M. J. Cowan]], [[J. Kurtzberg]], [[C. G. Steward]], [[P. A. Veys]] & [[A. H. Filipovich]] | | author = [[M. Eapen]], [[C. A. DeLaat]], [[K. S. Baker]], [[M. S. Cairo]], [[M. J. Cowan]], [[J. Kurtzberg]], [[C. G. Steward]], [[P. A. Veys]] & [[A. H. Filipovich]] | ||
Revision as of 19:29, 12 October 2018
|
Immunodeficiency Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2], Anmol Pitliya, M.B.B.S. M.D.[3]
Overview
Classification
| Diseases of Immune Dysregulation | |||||||||||||||||||||||||
| (A) Hemophagocytic lymphohistiocytosis (HLH) & EBV susceptibility | (B) Syndromes with Autoimmunity and Others | ||||||||||||||||||||||||
Hemophagocytic Lymphohistiocytosis (HLH) & EBV Susceptibility
| Diseases Of Immune Dysregulation: (A) Hemophagocytic Lymphohistiocytosis (HLH) & EBV Susceptibility | |||||||||||||||||||||||||||||||||||||||||||||
| Hemophagocytic Lymphohistiocytosis(HLH) | Susceptibility to EBV | ||||||||||||||||||||||||||||||||||||||||||||
| Hypopigmentation | Familial Hemophagocytic Lymphohistiocytosis Syndromes | EBV Associated with HLH | |||||||||||||||||||||||||||||||||||||||||||
| Chediak Higashi Syndrome:LYST | Perforin Deficiency(FHL2) | RASGRP1 Deficiency | XL,XLP1.SH2DIA | ||||||||||||||||||||||||||||||||||||||||||
| Griscelli Syndrome type2:RAB27a | UNCBD/Munc13-4 deficiency(FHL3) | CD70 Deficiency | XL,XLP2,XIAP | ||||||||||||||||||||||||||||||||||||||||||
| Hermansky Pudlak Syndrome type2:AP3B1 | Syntaxin II Deficiency(FHL4) | CTPS1 Deficiency | AR, CD27 Deficiency | ||||||||||||||||||||||||||||||||||||||||||
| Hermansky Pudlak Syndrome type10 | STXBP2/Munc18-2 Deficiency | RLTPR (CARMIL2) Deficiency | FAAP24 Deficiency | ||||||||||||||||||||||||||||||||||||||||||
| ITK Deficiency | |||||||||||||||||||||||||||||||||||||||||||||
| MAGT1 Deficiency | |||||||||||||||||||||||||||||||||||||||||||||
| PRKCD Deficiency | |||||||||||||||||||||||||||||||||||||||||||||
Syndromes with Autoimmunity and Others
| Diseases of Immune Dysregulation: (B) Syndromes with Autoimmunity and Others | |||||||||||||||||||||||||||||||||||||||||||||||||
| Syndromes with Autoimmunity | Immune Dysregulation with Colitis: IBD, Normal Tc & Bc | ||||||||||||||||||||||||||||||||||||||||||||||||
| Increased CD4-CD8-TCR alpha/beta (Double Negative T cells) | IL10 Deficiency, IL10, AR | IL10Ra Deficiency, IL10RA, AR | IL10Rb Deficiency, IL10RB, RA | NFATS haploinsufficiency, NAFTS, AD | |||||||||||||||||||||||||||||||||||||||||||||
| Yes | Occassionally | NO: Regulatory T cells Defects? | |||||||||||||||||||||||||||||||||||||||||||||||
| ALPS, Autoimmune Lymphoproliferative Syndrome | LRBA Deficiency | NO | YES | ||||||||||||||||||||||||||||||||||||||||||||||
| ALPS-FAS TNFRSF, AD or AR | STAT3 GOF mutation,STAT3 AD | Autoimmune Polyendocrinopathy with candidiasis & ectodermal dystrophy: APECED (APS-1) | IPEX Immune dysregulation, Polyendocrinopathy,enteropathy,X-linked FOXP-3 | ||||||||||||||||||||||||||||||||||||||||||||||
| ALPS-FASLG TNFSF6, AR | ITCH Deficiency, ITCH, AR | CD25 Deficiency, IL2RA, AR | |||||||||||||||||||||||||||||||||||||||||||||||
| ALPS-Caspase10, Casp10, AD | ZAP70 combined hylomorphic and activation mutations, ZAP70, AR | CTLA4 deficiency (ALPSV) CTLA4, AD | |||||||||||||||||||||||||||||||||||||||||||||||
| ALPS-Caspase8, Casp8, AR | Tripeptidyl-peptidase II deficiency, TPP2, AR | BACH2 deficiency. BACH2, AD | |||||||||||||||||||||||||||||||||||||||||||||||
| FADD deficiency, FADD, AR | JAK1 GOF, JAK1, AD | ||||||||||||||||||||||||||||||||||||||||||||||||
| Prolidase deficiency. PEPD, AR | |||||||||||||||||||||||||||||||||||||||||||||||||
Chediak Higashi Syndrome
- Chediak Higashi syndrome is caused by homozygous or compound heterogenous autosomal recessive mutation in the lysosomal trafficking gene (LYST:606897) on chromosome 1q42.[1]
- It is characterized by photophobia, nystagmus, partial albinism, neutropenia, abnormal susceptibility to infections and malignant lymphoma, large eosinophilic peroxidase positive inclusion bosides in myeloblasts and promyelocytes of bone marrow.[2]
- The most effective treatment is hematopoeitic stem cell transplantation.[3]
- For more information on Chediak Higashi syndrome, click here.
Griscelli Syndrome type 2
References
- ↑ M. D. Barbosa, Q. A. Nguyen, V. T. Tchernev, J. A. Ashley, J. C. Detter, S. M. Blaydes, S. J. Brandt, D. Chotai, C. Hodgman, R. C. Solari, M. Lovett & S. F. Kingsmore (1996). "Identification of the homologous beige and Chediak-Higashi syndrome genes". Nature. 382 (6588): 262–265. doi:10.1038/382262a0. PMID 8717042. Unknown parameter
|month=ignored (help) - ↑ Kaplan, Jerry; De Domenico, Ivana; Ward, Diane McVey (2008). "Chediak-Higashi syndrome". Current Opinion in Hematology. 15 (1): 22–29. doi:10.1097/MOH.0b013e3282f2bcce. ISSN 1065-6251.
- ↑ M. Eapen, C. A. DeLaat, K. S. Baker, M. S. Cairo, M. J. Cowan, J. Kurtzberg, C. G. Steward, P. A. Veys & A. H. Filipovich (2007). "Hematopoietic cell transplantation for Chediak-Higashi syndrome". Bone marrow transplantation. 39 (7): 411–415. doi:10.1038/sj.bmt.1705600. PMID 17293882. Unknown parameter
|month=ignored (help)